Claritev Q3 revenue jumps 9.1% to $268.3 million
By Brie CarterKey points
- Claritev reported third-quarter 2026 revenue of US$268.3 million, up 9.1% year-over-year, while its net loss narrowed to US$61.8 million.
- Adjusted EBITDA increased 4.4% to US$162 million, but its margin declined to 60.4%, and free cash flow worsened to negative US$25.8 million.
- Claritev increased its 2026 revenue guidance to US$1.038 billion–US$1.043 billion, adjusted EBITDA guidance to US$625 million–US$630 million and free cash flow guidance to US$10 million–US$20 million.
Claritev (NYSE:CTEV) reported third-quarter 2026 revenue of US$268.3 million, up 9.1% year-over-year, while its net loss narrowed to US$61.8 million.
Revenue increased from US$246 million a year earlier, while the net loss narrowed from US$69.8 million and diluted loss per share improved to US$3.64 from US$4.23.
Adjusted EBITDA, a non-GAAP earnings measure, increased 4.4% to US$162 million, but its margin declined to 60.4% from 63.1%, while operating cash flow fell to US$18.1 million and free cash flow worsened to negative US$25.8 million.
Claritev raised its 2026 revenue guidance to US$1.038 billion–US$1.043 billion and adjusted EBITDA guidance to US$625 million–US$630 million
Claritev provides healthcare technology, data and analytics services designed to help health plans and other customers manage healthcare costs, pricing and provider network arrangements.
The company also introduced preliminary 2027 revenue expectations of US$1.1 billion, which its management described as approximately one year ahead of its March 2026 Investor Day plan.
